CD274 and neoplasm: In terms of survival outcomes, such as OS, a study utilizing the CheckMate 040 cohort showed improved OS for tumors with PD-L1 ≥1% in tumor cells compared to those with PD-L1 <1%, which is consistent with the results from our study (36).